This from another one of those free CME sites that cater to doctors. It is from CCO's review of the AACR Meeting-
The key points are that profiling identified a target in 98% patients (often those that otherwise would not have been suspected; some tumor shrinkage in 47% - mostly stability, but 10% with partial or complete responses.
"In the 66 patients treated according to molecular profiling results, 27% (95% CI: 17% to 38%) had a progression-free survival ratio ≥ 1.3 (P = .007, 1-sided sample). The null hypothesis was that ≤ 15% of patients would have a progression-free survival ratio ≥ 1.3; these results reject the null hypothesis and lend support to the molecular profiling approach. The investigators were encouraged to see that the median overall survival for patients with a progression-free survival ratio ≥ 1.3 was significantly longer than that for the overall cohort (9.7 vs 5.0 months, respectively; P = .026). Molecular profiling identified a target in 98% of patients. The targets were often surprising and not those that normally would have been suspected, such as 1 patient who was successfully treated with diethylstibestrol for metastatic breast cancer. The overall response rate in the cohort was 10% (2% with a complete response, 8% with a partial response), and 21% of individuals were progression free at 4 months. Some tumor shrinkage was seen at some point during therapy in 47% of patients. Interestingly, for all 18 patients who had a progression-free survival ratio ≥ 1.3, the treatment that would have been selected by the treating physician did not match the therapies identified by molecular profiling."
Evidence of Benefit with Molecular Profiling
Molecular Studies of Tumor Samples
Jump to
- Welcome to CureASPS.org!
- ↳ Guest Book
- ↳ Forum Issues and Suggestions
- News and Updates
- ↳ Personal Stories and Updates
- ↳ Success Stories
- ↳ Rest In Peace
- ↳ Anonymous Patient Updates
- ↳ Chinese group news
- ↳ Medical Publications
- ↳ Other Publications
- ↳ Sarcoma Meetings and Conferences
- ASPS Clinical Trials
- ↳ Other Clinical Trials
- ↳ COMPLETED - ARQ 197 Clinical Trial
- ↳ COMPLETED - Dana Farber Vaccine Clinical Trial (GVAX)
- ↳ Dasatinib
- ↳ Alisertib
- ↳ Cediranib
- ↳ Anlotinib
- ↳ Immune checkpoint inhibitors (ICI)
- ↳ Axitinib and Pembrolizumab (Keytruda) in Miami, US
- ↳ TECENTRIQ (atezolizumab) by Genentech
- ↳ Pfizer's PF-06801591
- ↳ Durvalumab+Tremelimumab at MDACC
- Symptoms and Diagnostics
- ↳ Symptoms
- ↳ Scan Types and Follow-Up
- ↳ Molecular Studies
- ↳ Pathology results
- Primary Tumor Treatment
- ↳ Resection
- ↳ Treatment of Non-Resectable Primary Tumor
- ↳ Radiation
- Systemic Treatment
- ↳ TKI
- ↳ Sutent (sunitinib)
- ↳ Pazopanib
- ↳ Сabozantinib (Cometriq)
- ↳ Sorafenib
- ↳ Chemotherapy
- ↳ Metronomic chemotherapy
- ↳ Temozolomide (Temodar)
- ↳ Side effects of systemic treatments
- ↳ Interferon alpha
- ↳ Immune checkpoint inhibitors ICI (PD-1 and PD-L1 targeting drugs)
- ↳ Keytruda
- ↳ Opdivo
- ↳ TECENTRIQ (atezolizumab)
- ↳ Toxicity, problems and potentiation strategies
- ↳ Treatment response criteria and evaluation/scanning problems/rare cases
- ↳ treatment discontinuation/re-treatment
- Metastatic Disease Treatment
- ↳ Local treatment modalities
- ↳ cryoablation
- ↳ Side effects/complications of the local ablations
- ↳ Radiosurgery
- ↳ Microwave ablation
- ↳ High intensity focused ultrasound (HIFU)
- ↳ Lung Metastases
- ↳ Laser assisted surgery
- ↳ Brain Metastases
- ↳ Bone Metastases
- ↳ Other Metastases
- ↳ Abdominal Metastases
- ↳ Liver metastases
- ↳ Heart Metastases
- ↳ Spinal metastases
- ↳ Adrenal metastases
- ↳ Pancreatic metastases
- Living with ASPS
- ↳ Insurance Coverage
- ↳ Second opinion from a sarcoma center
- ↳ Finanical assistance
- ↳ Diet and lifestyle
- ↳ Related studies
- ↳ Pain management
- ↳ Travel assistance